Navigation Links
ShangPharma Announces First Quarter 2012 Results
Date:5/17/2012

ements in this press release. The Company expects to face potential risks and uncertainties related to its ability to, among other things, attract, train, motivate and retain skilled scientists; diversify its customer base and adapt to potential loss of sales to, or significant reduction in orders from, any of its major customers; adapt its business to industry trends, such as fluctuations in the R&D budgets of pharmaceutical and biotechnology industry participants; protect the intellectual property rights of its customers; comply with applicable regulations and industry standards; compete effectively in its industry, which may subject it to increasing pricing pressure and reduce the demand for its services; expand and market its services and manage its growth; and develop and maintain effective internal control over financial reporting; as well as other risks outlined in the Company's filings with the U.S. Securities and Exchange Commission. All information provided in this press release and in the attachments is as of the date of this press release, and the Company does not undertake any obligation to update any such information, except as required under applicable law.

About Non-GAAP Financial Measures To supplement the Company's consolidated financial results presented in accordance with United States Generally Accepted Accounting Principles ("GAAP"), the Company uses the following non-GAAP financial measures: (1) gross profit, (2) gross margin, (3) profit from operations, (4) operating expenses, (5) operating margin, (6) net income, and (7) diluted earnings per ADS, each of which excludes expenses relating to or the effect of share-based compensation. The presentation of these non-GAAP financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with GAAP. For more information on these non-GAAP financial measures, please see the table captioned "Reconciliatio
'/>"/>

SOURCE ShangPharma Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. ShangPharma to Report First Quarter 2012 Financial Results on May 17, 2012
2. ShangPharma Corporation Files 2011 Annual Report on Form 20-F
3. ShangPharma to Report Fourth Quarter and Full Year 2011 Financial Results on March 13, 2012
4. ShangPharma to Present at Cowens 32nd Annual Health Care Conference
5. ShangPharma Announces Milestone Achievement in Research Partnership with Hengrui
6. ShangPharma Announces Opening of New Facility to Support Lillys Pipeline
7. ShangPharma to Attend Two Upcoming Investor Conferences
8. ShangPharma Announces Third Quarter 2011 Results
9. ShangPharma Purchases Shanghai In-vivo Drug Research Facility from Charles River
10. ShangPharma Corporation Announces Shareholder Resolutions Adopted at 2011 Annual General Meeting
11. ShangPharma Corporation Announces Resignation of a Director
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... Pa. , May 4, 2015 DePuy ... Dura Repair, the first commercially available biosynthesized dural ... Synthes CMF is a part of the DePuy Synthes ... is a tissue membrane that covers and protects the ... be cut to allow surgeons to access the brain. ...
(Date:5/4/2015)... ANGELES , May 4, 2015 Former ... FOX News online last week where he discussed Theradome™, ... to be FDA-cleared. The FOX segment shows firsthand how, ... and affordable hair loss solution that will not require ... stimulates the mitochondria at the base of the hair ...
(Date:5/4/2015)... TORONTO , May 4, 2015 /PRNewswire/ ... announced that it intends to dividend to its stockholders ... of a definitive licensing agreement to license its RapidMist™ ... ) (OTCQB:SMFI). As announced on April 23, ... in respect of the licensing of its RapidMist™ buccal ...
Breaking Medicine Technology:DePuy Synthes CMF Launches First Biosynthesized Cellulose-Based Dural Replacement For Neurosurgery 2DePuy Synthes CMF Launches First Biosynthesized Cellulose-Based Dural Replacement For Neurosurgery 3FOX News Features Theradome as the Take-Home Solution to Tackle Baldness 2Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 2Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 3Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 4Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 5
... Aug. 21 Genetic testing can be,used to ... anticoagulant, according to research published in the,September 1, ... American Society of,Hematology. This result represents one of ... to guide personal medical care., Because individuals ...
... Randomized, Double-Blind Study Targets Biomarker-Defined Population, ... (Nasdaq: GNTA ) announced that the ... confirmatory Phase 3 trial of Genasense,(oblimersen sodium) ... as,AGENDA, is a randomized, double-blind, placebo-controlled study ...
Cached Medicine Technology:Genetics Determine Optimal Drug Dose of Common Anticoagulant 2Genetics Determine Optimal Drug Dose of Common Anticoagulant 3Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma 2Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma 3Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma 4Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma 5
(Date:5/4/2015)... HHT is a rare but cruel ... it can have seemingly mild symptoms like frequent nosebleeds, ... Hereditary Hemorrhagic Telangiectasia (HHT) is a hereditary disorder resulting ... capillary connections between an artery and a vein. These ... but may also be present in the lungs, brain ...
(Date:5/4/2015)... New York (PRWEB) May 04, 2015 ... as $2.4 billion to settle thousands of Actos lawsuits ... diabetes medication increases the risk that a patient will ... on April 28th, if 95% of those eligible for ... resolve nearly 9,000 bladder cancer cases currently pending in ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 “ LiveSchool ... monthly AppWatch, which takes a look at the latest ... and Windows. Joe Toohey, the host of AppWatch and ... viewers how this application allows teachers to reward students ... than some realize, especially in the classroom. And ...
(Date:5/4/2015)... May 04, 2015 Baptist Medical ... Stroke Association’s Get With The Guidelines®-Stroke Gold Plus ... Honor Roll. The award recognizes the hospital’s commitment ... the most appropriate treatment according to nationally recognized, ... , To receive the Gold Plus Quality Achievement ...
(Date:5/4/2015)... Ticket Down is a reputable source for authentic ... While the World Cup is the most known soccer ... the International Champions Cup is one of the biggest tournaments ... record for soccer in the United States set when Manchester ... University of Michigan. This year, the defending champion Manchester United ...
Breaking Medicine News(10 mins):Health News:Frequent Nosebleeds Can Be a Sign of a Rare Undiagnosed Disease - Cure HHT 2Health News:Frequent Nosebleeds Can Be a Sign of a Rare Undiagnosed Disease - Cure HHT 3Health News:Actos Lawsuit Settlement: Takeda Pharmaceutical Co. to Pay As Much As $2.4 Billion to Resolve Claims Alleging Actos Causes Bladder Cancer 2Health News:Actos Lawsuit Settlement: Takeda Pharmaceutical Co. to Pay As Much As $2.4 Billion to Resolve Claims Alleging Actos Causes Bladder Cancer 3Health News:An Application for Teachers to Reward Students with Good Behavior Was Featured on NewsWatch Television 2Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 2Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 3Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 4Health News:Cheap 2015 International Champions Cup (ICC) Tickets: Ticket Down Slashes Ticket Prices on International Champions Cup (ICC) Presale Tickets 2Health News:Cheap 2015 International Champions Cup (ICC) Tickets: Ticket Down Slashes Ticket Prices on International Champions Cup (ICC) Presale Tickets 3Health News:Cheap 2015 International Champions Cup (ICC) Tickets: Ticket Down Slashes Ticket Prices on International Champions Cup (ICC) Presale Tickets 4
... , ... Strong Backbone for Victory: Cortical Concepts Wins ,Wharton Business Plan Competition Michelson Grand ... “People’s Choice” Award with Private Sales for Co-eds, , ... Philadelphia, PA (PRWEB) April 29, ...
... ... Science and Technology Policy, will bring together leaders in open innovation , ... Washington, DC (Vocus) -- This ... Grant Making”, a public-private strategy session jointly hosted by the White House Office on ...
... Athens, Ga. A team of researchers at the University ... the next five years from the National Institutes of Health ... may prevent drug abuse relapse. "Drug abuse is ... aspects of treating addiction is preventing the relapse caused by ...
... ... awarded a $4.2 million grant from the Ontario Ministry of Research and Innovation’s Biopharmaceutical ... expansion of its bio-manufacturing facility in Mississauga, Ontario, Canada. , ... Toronto, ON (Vocus) April 30, 2010 -- ...
... how the brain communicates with limbs, researcher says , THURSDAY, ... a phenomenon known as mirror movements has been identified by ... move one side of their body without moving the other. ... the same movement occurs unintentionally in the left hand. , ...
... ... has developed a unique caregiver testing program to measure the preparedness of home care ... ... 29, 2010 -- The National Private Duty Association (NPDA), a non-profit organization comprised of ...
Cached Medicine News:Health News:Wharton Business Plan Competition Michelson Grand Prize Winners Announced 2Health News:Wharton Business Plan Competition Michelson Grand Prize Winners Announced 3Health News:Prize4Life Featured in Major Innovation/Prize National Conference 2Health News:Prize4Life Featured in Major Innovation/Prize National Conference 3Health News:UGA, Emory to study how exercise may prevent drug abuse relapse 2Health News:Therapure Awarded $4.2 Million BIP Grant from the Ontario Government 2Health News:Scientists Find Cause of Involuntary Mirror Movements 2Health News:Association Advocates Testing for Home Care Workers 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: